<SEC-DOCUMENT>0001384101-18-000002.txt : 20180108
<SEC-HEADER>0001384101-18-000002.hdr.sgml : 20180108
<ACCEPTANCE-DATETIME>20180108080846
ACCESSION NUMBER:		0001384101-18-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180108
DATE AS OF CHANGE:		20180108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERACYTE, INC.
		CENTRAL INDEX KEY:			0001384101
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				205455398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36156
		FILM NUMBER:		18514919

	BUSINESS ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 243-6300

	MAIL ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALDEROME INC
		DATE OF NAME CHANGE:	20061219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vcyt-11818xkreaffirmguidan.htm
<DESCRIPTION>VCYT 8-K 1.8.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7256C1ADB27A4632F536D1C72DF46571"></a></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;-sec-extract:summary;"><hr></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;"><hr></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C.  20549</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  January 8, 2018</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;font-weight:bold;">VERACYTE, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DELAWARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-36156</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20-5455398</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:22%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6000 Shoreline Court, Suite&#160;300, South San Francisco, California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94080</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(650) 243-6300</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company  </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;"><hr></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;"><hr></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02 Results of Operations and Financial Condition.</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2018, Veracyte,&#160;Inc. (the &#8220;Company&#8221;) issued a press release (the &#8220;Press Release&#8221;) that, among other disclosures described below under Item 8.01 of this Current Report on Form 8-K, reaffirmed annual revenue and cash burn guidance for the fiscal year ended December 31, 2017 that was previously provided by the Company on November 6, 2017. The Press Release also discloses the Company&#8217;s expected fourth quarter 2017 genomic test volume for its Afirma</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and Percepta</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;classifiers. The full text of the press release is furnished as Exhibit&#160;99.1 to this report.</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this Item 2.02, including such information contained in Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01 Regulation FD Disclosure.</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;January 8, 2018, the Company will make available on its website an&#160;Investor Presentation, which includes business information, including the disclosure described above under Item 2.02 of this Current Report on Form 8-K. The presentation can be accessed by going to www.veracyte.com, selecting the &#8220;Investors&#8221; tab, and then selecting the &#8220;Events &amp; Presentations&#8221; tab. The presentation will be available on the Company&#8217;s website until the next regular update.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this Item 7.01 is furnished pursuant to Item 7.01 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.</font></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the disclosure described above under Item 2.02 of this Current Report on Form 8-K, the Press Release also discloses key business initiatives, including strategic realignments to the Company&#8217;s corporate structure and new appointments, to advance commercial growth of its three market-leading genomic tests. </font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;Exhibits</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-18188xkexhibit991.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vcyt-18188xkexhibit991.htm"><font style="font-family:inherit;font-size:10pt;">Press release issued by Veracyte, Inc. dated January 8, 2018.</font></a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:29%;"></td><td style="width:8%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 8, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VERACYTE,&#160;INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Keith S. Kennedy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keith S. Kennedy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vcyt-18188xkexhibit991.htm
<DESCRIPTION>VCYT - 8-K 1.8.18 EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0DDA1244D435B182A313D1C732604071"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="veracytelogoa02.jpg" alt="veracytelogoa02.jpg" style="height:102px;width:136px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Company Reiterates 2017 Revenue and Cash Burn Guidance </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">SOUTH SAN FRANCISCO, Calif., January 8, 2018 --- Veracyte, Inc. (NASDAQ: VCYT) today announced key business initiatives, including strategic realignments to its corporate structure and new appointments, to advance commercial growth of its three market-leading genomic tests. The company also reiterated its previous 2017 revenue and cash burn guidance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">Veracyte is consolidating its clinical, medical and research and development functions into one department to ensure a strong, consistent focus on addressing unmet customer needs and supporting the sales and marketing team. The new scientific, clinical and medical affairs department will be headed by Giulia C. Kennedy, Ph.D., who has served as chief scientific officer since the company&#8217;s founding in 2008. Veracyte has also expanded its sales team to 73 specialists under the direction of eight regional sales directors who will report directly to John Hanna, the company&#8217;s chief commercial officer. In addition, the company has appointed Jessica Meng as vice president of marketing. Ms. Meng comes to Veracyte from Genentech where she led marketing for Avastin</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;in oncology.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;Our company is at a unique moment in time, in which we have market-leading and first-to-market tests in three largely untapped clinical markets,&#8221; said Bonnie Anderson, chairman and chief executive officer of Veracyte. &#8220;We believe these strategic realignments and new appointments will enable us to more actively manage the dynamics of our business and focus our investments to optimize these significant commercial opportunities.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">Veracyte is reiterating its previous 2017 annual revenue guidance of $71 million to $72 million and its annual cash burn guidance of $25 million to $26 million. The annual cash burn guidance excludes the $1.5 million exit fee for the refinance of its senior secured credit facility. Cash burn is defined as the sum of net cash used in operating activities and net capital expenditures. The company also announced that it expects fourth quarter 2017 reported genomic test volume for its Afirma</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;and Percepta</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;classifiers to be approximately 7,100 tests - a 12.5% increase compared to the fourth quarter of 2016. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Afirma and Percepta are used to improve the diagnosis of thyroid cancer and lung cancer, respectively, without the need for invasive, risky and expensive surgery. The company&#8217;s third product - the Envisia&#8482; Genomic Classifier - is positioned to gain Medicare coverage in 2018 and is similarly used to improve the diagnosis of idiopathic pulmonary fibrosis. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">About&#160;Veracyte</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our 2017 revenue and cash burn guidance and expected genomic test volume, our ability to manage our future business and optimize our commercial opportunities, and the expected utility and benefits of our tests, including our belief that the use of our tests will enable the diagnosis of disease without the need for invasive, risky and expensive surgical procedure. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the benefits of our tests, the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the&#160;Food and Drug Administration&#160;or other regulatory bodies; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products is able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in the company's filings with the&#160;Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended&#160;September 30, 2017. These forward-looking statements speak only as of the date hereof and&#160;Veracyte&#160;specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Media:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tracy Morris, 650-380-4413</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">tracy.morris@veracyte.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Investors:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jackie Cossmon, 650-243-6371</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">jackie@veracyte.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>veracytelogoa02.jpg
<TEXT>
begin 644 veracytelogoa02.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $! 54# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?P71'[+E.6TLIP=/!T=H[ON^K^?_   HHHKSCUPHHHH **** "BBB@ HHHH
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M@?-XS%X7!Q=2K44(]Y-(]*K"\7^.M \!:;]N\0:K;Z7;'(4S-\SD=E4<L?8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$]UXZ\0HNI:_J=W\]Q)/)\YB+GG";L8SRVX]Z .#L]'_ &R?&D8U"X\0^ /
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M11QWX1IM+U$C#V5T!\D@8<@9P& ZC/M0!ZE17SG^PG\6-:^)7P7;2_%/F?\
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M%?C'XD_MX?''2_#7Q2OOAAK$<5G>&2SL?M#WML8H@!_K8\!-\?KG=VQ7K_\
MPQW\<?\ HZWQ#_X(_P#[KJ']KK0-?^"?QB\*_M%^%=,_M6RTRV_LCQ7I]NI\
MV6Q9N)@!UV@G)/0I%G*@X^FOAC\5?"WQB\)V?B/PEJ\&K:9<H&W1MB2)NZ2)
MU1QW4TP/FO\ X8[^./\ T=;XA_\ !'_]UT?\,=_''_HZWQ#_ ."/_P"ZZ^P*
M^??VLOVG['X)^&3H.@-_;/Q.UQ?LFB:'9XEG65\!9I$'*J-V1D?,1@<9(0%K
M]E?]F74/V<X_&+ZIXWF\<7_B6_34+B[FL/LC+* P9B/-DW%BV2>.E>\5YC\&
M]"\;> /@KIL/BV^O/&WCE+9KF]$D\0>2=OF\A')" +P@)(!P3WKC=8_:R_X1
MOX=:IXSUCP!KEGIEEJYT-8H[FUGFGNEO'LY$14D/W98VY/WAC&: /H"BO)X_
MVC_#=[\:- ^'.GP76H7VKZ3_ &NNI0;3:Q1E&D1&;.2[(NX #HRGO7K% !11
M10 4444 %%%% !1110 4444 ?/7A#]BGP;X-_:2U?XQ6MW=2:I?//<)I;(@M
M[>XF $DJD#<2<R'![R'TKZ%HHH *\C^/7[+?P_\ VBK"-?%.EM'JUNFRTURP
M80WML,Y 5\'< 23M8$<GC/->N44 ?)=G^R9\:?#$(L_#?[2^NQ::@V11:QI,
M=_*B#@#S'DSP*?9?L$IXPUVRU3XP_$OQ)\54LG,EOI-X_P!EL%<]S$K'_P =
M*Y[Y'%?6-% %32=)LM!TNTTW3;2&PT^TB6"WM;= D<4:C"JJC@  =*Y[XK_#
MVV^+'PW\1>#[VZFL;76K-[.2X@ +QJW4J#QGZUUE% '-_#7P1;_#7X?^'O"E
MI<R7EMHUC#8QW$P >18U"AF XR<=JZ2BB@#COBI\'_!_QK\,/H'C/0[?6]-+
M>8BS K)"^"-\<BD,C8)&5(."1TKYWTW]BGX@?#R$6'PW_:"\3>'M#CXMM+U:
MTCU&.W7/W5W,H ^BBOKFB@#Y'U#]B+QG\1E6S^*/QY\3^*]"9@T^D:9;IIT%
MQ@YVN%9@1^&?0CK7J?C#]E3P3KOP%U+X3:%:+X0\.7QC9FTR,-(&61)-[%\E
MV)0 LQ)Q]!7LM% &9X7T*/POX9TG1H96FBTZTALTD< ,ZQH$!..Y J;6]$T_
MQ)I%YI6JV4&HZ;>1-#<6EU&)(Y488*LIX((J[10!\G7G[!?_  ANM7FH_![X
MG>)/A9%>/YLVD6K_ &NP+^HB9A_X\6]L#BDN/V3?C/XDC^R>)OVE]>FTYQLE
MCT72H["5T/!'F))GD9YYKZRHH \H^ _[,/@']G739(?">EM_:5Q&([S6;Y_.
MO;K!S\\F  ">=JA5SVKU>BB@!&8*I). .237P?\ L9_#_1?B9^U5\7_C;IEL
MD.@0:G-IFB[/F6:9P/M%PI[9 R,?\]SZ5[1^W;\7+OX7_ ;4+/1DEF\4>*95
MT'2H8/\ 6>9,"'8=\A-V,?Q,M>@?LX_".W^!OP6\+>#84C%Q8VH:\DCY$MT_
MSS-GO\[''L!Z4 >DT444 >9?&KX%:=\;+GP5-?ZG=:<?"^NV^NP"V56\Z2(Y
M"-GHI]N:]-HHH 9-#'<0O%*BRQ2*5='&58'@@CN*^6/%7[ /A^T\63>*/A5X
MNUSX0:W.NV>/09,V<HSG!AR,#/\ "&V\#Y:^JJ* /D^3]ESX[ZE']EU#]IS5
MOL70_8-"BMY\?]=%DSGWKO\ X#_L?>!/@/J,VNVBWGB7QE<EVN?$^O3?:+QR
M_P!_:<80'G) W$'EC7N-% !7E.H? .UU+P=:>'Y=5D,,'C%O%QD, .]CJKZ@
M8",_=RYCW>@SCM7JU% 'A/PR_9/TCX7^)/#VK6&M75V^CW.H2J+F,,\D,\,<
M$$&[/"P0Q1HOK@GC->[444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 13VD%TT;30QRM&=R&
M1 Q4^HSTJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
